Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis

被引:83
作者
Doherty, TM [1 ]
Olsen, AW [1 ]
van Pinxteren, L [1 ]
Andersen, P [1 ]
机构
[1] Statens Serum Inst, Dept TB Immunol, DK-2300 Copenhagen, Denmark
关键词
D O I
10.1128/IAI.70.6.3111-3121.2002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Immunity against Mycobacterium tuberculosis depends largely on activation of cell-mediated responses, and gamma interferon has been shown to play a crucial role in this process in both humans and animal models. Since the lung is normally the organ in which infection is initiated and is the major site of pathology, immune responses in the lung play a significant role in restricting initial infection with M. tuberculosis. The aim of the present study was to stimulate efficient immunity in the lung by targeting the gut mucosa. Detoxified monophosphoryl lipid A (MPL) has been shown to be a relatively nontoxic adjuvant which efficiently promotes the induction of type 1 responses when it is given by the traditional subcutaneous route. We have therefore compared subcutaneous immunization of mice to oral immunization by using a model subunit vaccine carrying two immunodominant proteins from M. tuberculosis, in combination with MPL-based adjuvants. While less effective when used to prime a response, a heterologous priming and boosting vaccination strategy employing oral boosting induced significant systemic type 1 responses which equaled and surpassed those attained by subcutaneous immunization protocols. Moreover, the increased immune responses observed correlated with the induction of substantial protection against subsequent aerosol infection with virulent M. tuberculosis at levels comparable to, or better than, those obtained by multiple subcutaneous vaccinations. These results demonstrate that booster vaccinations via mucosal surfaces, by combining efficient subunit vaccines with the potent adjuvant MPL, may be an effective method of addressing some of the shortcomings of current vaccination strategies.
引用
收藏
页码:3111 / 3121
页数:11
相关论文
共 36 条
[1]   Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen [J].
Akbari, O ;
DeKruyff, RH ;
Umetsu, DT .
NATURE IMMUNOLOGY, 2001, 2 (08) :725-731
[2]   TB vaccines: progress and problems [J].
Andersen, P .
TRENDS IN IMMUNOLOGY, 2001, 22 (03) :160-168
[4]  
[Anonymous], 1995, RELEVE EPIDEMIOLOGIQ, V70, P229
[5]   Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii [J].
Bonenfant, C ;
Dimier-Poisson, I ;
Velge-Roussel, F ;
Buzoni-Gatel, D ;
Del Giudice, G ;
Rappuoli, R ;
Bout, D .
INFECTION AND IMMUNITY, 2001, 69 (03) :1605-1612
[6]   Strategies for mucosal vaccine development [J].
Boyaka, PN ;
Marinaro, M ;
Vancott, JL ;
Takahashi, I ;
Fujihashi, K ;
Yamamoto, M ;
van Ginkel, FW ;
Jackson, RJ ;
Kiyono, H ;
McGhee, JR .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1999, 60 (04) :35-45
[7]   Failure of the Mycobacterium bovis BCG vaccine:: Some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis [J].
Brandt, L ;
Cunha, JF ;
Olsen, AW ;
Chilima, B ;
Hirsch, P ;
Appelberg, R ;
Andersen, P .
INFECTION AND IMMUNITY, 2002, 70 (02) :672-678
[8]   ESAT-6 subunit vaccination against Mycobacterium tuberculosis [J].
Brandt, L ;
Elhay, M ;
Rosenkrands, I ;
Lindblad, EB ;
Andersen, P .
INFECTION AND IMMUNITY, 2000, 68 (02) :791-795
[9]  
COLDITZ GA, 1995, PEDIATRICS, V96, P29
[10]   Mucosal immunity and tolerance: relevance to vaccine development [J].
Czerkinsky, C ;
Anjuere, F ;
McGhee, JR ;
George-Chandy, A ;
Holmgren, J ;
Kieny, MP ;
Fujiyashi, K ;
Mestecky, JF ;
Pierrefite-Carle, V ;
Rask, C ;
Sun, JB .
IMMUNOLOGICAL REVIEWS, 1999, 170 :197-222